The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial

(2019) R S Herbst et al.   ANNALS OF ONCOLOGY

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project

(2019) Keith M Kerr et al.   LUNG CANCER

Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer

(2018) H Wang et al.   ANNALS OF ONCOLOGY

Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations

(2018) Bryce Noll et al.   CANCER CYTOPATHOLOGY

Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas

(2018) Eleanor Russell-Goldman et al.   CANCER CYTOPATHOLOGY

Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients

(2018) Marius Ilie et al.   CANCER CYTOPATHOLOGY

PD-L1 immunoexpression in matched biopsy and liquid based cytology samples of advanced stage non-small cell lung carcinomas

(2018) Deepali Jain et al.   CYTOPATHOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay

(2018) Matthew Evans et al.   PATHOLOGY & ONCOLOGY RESEARCH

Assessment of Programmed Death–Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non–Small Cell Lung Carcinoma

(2018) Andrea Hernandez et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non–Small Cell Lung Cancer

(2018) Peng Song et al.   JOURNAL OF IMMUNOTHERAPY

Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer

(2018) Elisa Capizzi et al.   LUNG CANCER

Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features

(2018) Linda Ye et al.   MODERN PATHOLOGY

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

(2018) Yasushi Yatabe et al.   Journal of Thoracic Oncology

The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking

(2017) Birgit G Skov et al.   HISTOPATHOLOGY

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases

(2017) Hironori Uruga et al.   Journal of Thoracic Oncology

Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx

(2017) Birgit G. Skov et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer

(2015) Satoru Kitazono et al.   Clinical Lung Cancer

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population

(2014) Birgit G Skov et al.   APMIS